Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

How to Train your T cells: Overcoming Immune Dysfunction in Multiple Myeloma.

Cohen AD, Raje N, Fowler JA, Mezzi K, Scott EC, Dhodapkar MV.

Clin Cancer Res. 2019 Oct 31. pii: clincanres.2111.2019. doi: 10.1158/1078-0432.CCR-19-2111. [Epub ahead of print]

PMID:
31672768
2.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

3.

Evolution education is a complex landscape.

Dunk RDP, Barnes ME, Reiss MJ, Alters B, Asghar A, Carter BE, Cotner S, Glaze AL, Hawley PH, Jensen JL, Mead LS, Nadelson LS, Nelson CE, Pobiner B, Scott EC, Shtulman A, Sinatra GM, Southerland SA, Walter EM, Brownell SE, Wiles JR.

Nat Ecol Evol. 2019 Mar;3(3):327-329. doi: 10.1038/s41559-019-0802-9. No abstract available.

PMID:
30718854
4.

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV.

Haematologica. 2018 Dec;103(12):2079-2087. doi: 10.3324/haematol.2018.194118. Epub 2018 Sep 20.

5.

Bortezomib-based Chemotherapy for Multiple Myeloma Patients Without Comorbid Cardiovascular Disease Shows No Cardiotoxicity.

Heitner SB, Minnier J, Naher A, Van Woerkom RC, Ritts A, Ferencik M, Broberg C, Medvedova E, Silbermann R, Scott EC.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):796-802. doi: 10.1016/j.clml.2018.08.004. Epub 2018 Aug 14.

PMID:
30217616
6.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.

7.

Biallelic loss of human CTNNA2, encoding αN-catenin, leads to ARP2/3 complex overactivity and disordered cortical neuronal migration.

Schaffer AE, Breuss MW, Caglayan AO, Al-Sanaa N, Al-Abdulwahed HY, Kaymakçalan H, Yılmaz C, Zaki MS, Rosti RO, Copeland B, Baek ST, Musaev D, Scott EC, Ben-Omran T, Kariminejad A, Kayserili H, Mojahedi F, Kara M, Cai N, Silhavy JL, Elsharif S, Fenercioglu E, Barshop BA, Kara B, Wang R, Stanley V, James KN, Nachnani R, Kalur A, Megahed H, Incecik F, Danda S, Alanay Y, Faqeih E, Melikishvili G, Mansour L, Miller I, Sukhudyan B, Chelly J, Dobyns WB, Bilguvar K, Jamra RA, Gunel M, Gleeson JG.

Nat Genet. 2018 Aug;50(8):1093-1101. doi: 10.1038/s41588-018-0166-0. Epub 2018 Jul 16.

8.

The Mobile Element Locator Tool (MELT): population-scale mobile element discovery and biology.

Gardner EJ, Lam VK, Harris DN, Chuang NT, Scott EC, Pittard WS, Mills RE; 1000 Genomes Project Consortium, Devine SE.

Genome Res. 2017 Nov;27(11):1916-1929. doi: 10.1101/gr.218032.116. Epub 2017 Aug 30.

9.

The Role of Somatic L1 Retrotransposition in Human Cancers.

Scott EC, Devine SE.

Viruses. 2017 May 31;9(6). pii: E131. doi: 10.3390/v9060131. Review.

10.

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM.

Leuk Lymphoma. 2018 Jan;59(1):221-224. doi: 10.1080/10428194.2017.1320713. Epub 2017 May 30. No abstract available.

11.

Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.

Gay ND, Okada CY, Chen AI, Scott EC.

Ther Adv Hematol. 2017 May;8(5):175-180. doi: 10.1177/2040620717695723. Epub 2017 Mar 28. Review.

12.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.

Scott EC, Maziarz RT, Spurgeon SE, Medvedova E, Gajewski J, Reasor-Heard S, Park B, Kratz A, Thomas GV, Loriaux M, Cascio M, Podolak J, Gordon M, Botelho J, Stadtmauer E, Amaravadi R, Vogl DT.

Haematologica. 2017 Jul;102(7):e261-e265. doi: 10.3324/haematol.2016.162321. Epub 2017 Apr 6. No abstract available.

13.

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1893-1899. doi: 10.1016/j.bbmt.2016.07.007. Epub 2016 Aug 2.

14.

Biallelic Mutations in Citron Kinase Link Mitotic Cytokinesis to Human Primary Microcephaly.

Li H, Bielas SL, Zaki MS, Ismail S, Farfara D, Um K, Rosti RO, Scott EC, Tu S, Chi NC, Gabriel S, Erson-Omay EZ, Ercan-Sencicek AG, Yasuno K, Çağlayan AO, Kaymakçalan H, Ekici B, Bilguvar K, Gunel M, Gleeson JG.

Am J Hum Genet. 2016 Aug 4;99(2):501-10. doi: 10.1016/j.ajhg.2016.07.004. Epub 2016 Jul 21.

15.

Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making.

Clark CA, Cornell RF, Scott EC, Chung J, Costa LJ.

Am J Hematol. 2016 Oct;91(10):1044-51. doi: 10.1002/ajh.24478. Epub 2016 Jul 27. Review.

16.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J.

J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.

17.

A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer.

Scott EC, Gardner EJ, Masood A, Chuang NT, Vertino PM, Devine SE.

Genome Res. 2016 Jun;26(6):745-55. doi: 10.1101/gr.201814.115. Epub 2016 May 10.

18.

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM.

Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

PMID:
26778538
19.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.

D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P.

J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14.

20.

Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.

Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW.

Oncotarget. 2015 Aug 7;6(22):18921-32.

21.

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P.

N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.

22.

Sensitivity to change and concurrent validity of direct behavior ratings for academic anxiety.

von der Embse NP, Scott EC, Kilgus SP.

Sch Psychol Q. 2015 Jun;30(2):244-259. doi: 10.1037/spq0000083. Epub 2014 Oct 6.

PMID:
25286312
23.

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.

Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, Paul TM, Nichols CW, Porter DL, Kaplan J, Mallon G, Bradner JE, Amaravadi RK.

Autophagy. 2014 Aug;10(8):1380-90. doi: 10.4161/auto.29264. Epub 2014 May 20.

24.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974
25.

Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.

Sondhi D, Scott EC, Chen A, Hackett NR, Wong AM, Kubiak A, Nelvagal HR, Pearse Y, Cotman SL, Cooper JD, Crystal RG.

Hum Gene Ther. 2014 Mar;25(3):223-39. doi: 10.1089/hum.2012.253. Epub 2014 Mar 4.

26.

Climate in the classroom.

Scott EC, Berbeco M.

Sci Am. 2013 Oct;309(4):14. No abstract available.

PMID:
24137843
27.

This I believe: we need to understand evolution, adaptation, and phenotype.

Scott EC.

Front Genet. 2013 Jan 2;3:303. doi: 10.3389/fgene.2012.00303. eCollection 2012. No abstract available.

28.

Plummer-Vinson syndrome and reactive thrombocytosis mask a JAK2-V617F positive myeloproliferative neoplasm.

Scott EC, Schuster S.

Blood. 2011 Dec 1;118(23):5988. No abstract available.

PMID:
22238785
29.

Outcomes of reinterventions after subintimal angioplasty.

Schmieder GC, Richardson AI, Scott EC, Stokes GK, Meier GH 3rd, Panneton JM.

J Vasc Surg. 2010 Aug;52(2):375-82. doi: 10.1016/j.jvs.2010.03.008. Epub 2010 Jun 11.

30.

Dispatches from the evolution wars: shifting tactics and expanding battlefields.

Branch G, Scott EC, Rosenau J.

Annu Rev Genomics Hum Genet. 2010;11:317-38. doi: 10.1146/annurev-genom-082509-141815. Review.

PMID:
20504219
31.

Dobzhansky was right: let's tell the students.

Scott EC.

Bioessays. 2010 May;32(5):372-4. doi: 10.1002/bies.200900190. No abstract available.

PMID:
20414894
32.

Successful repair of a ruptured Stanford type B aortic dissection during pregnancy.

Stout CL, Scott EC, Stokes GK, Panneton JM.

J Vasc Surg. 2010 Apr;51(4):990-2. doi: 10.1016/j.jvs.2009.10.121. Epub 2010 Jan 4. Review.

33.

The latest face of creationism.

Branch G, Scott EC.

Sci Am. 2009 Jan;300(1):92-9. No abstract available.

PMID:
19186756
34.

Selective stenting in subintimal angioplasty: analysis of primary stent outcomes.

Schmieder GC, Richardson AI, Scott EC, Stokes GK, Meier GH 3rd, Panneton JM.

J Vasc Surg. 2008 Nov;48(5):1175-80; discussion 1180-1. doi: 10.1016/j.jvs.2008.05.080. Epub 2008 Sep 7.

35.

Subintimal angioplasty: Our experience in the treatment of 506 infrainguinal arterial occlusions.

Scott EC, Biuckians A, Light RE, Burgess J, Meier GH 3rd, Panneton JM.

J Vasc Surg. 2008 Oct;48(4):878-84. doi: 10.1016/j.jvs.2008.05.037. Epub 2008 Jun 30.

36.

Pre-existing cardiac disease, troponin I elevation and mortality in patients with severe sepsis and septic shock.

Scott EC, Ho HC, Yu M, Chapital AD, Koss W, Takanishi DM Jr.

Anaesth Intensive Care. 2008 Jan;36(1):51-9.

37.

The natural history of autologous fistulas as first-time dialysis access in the KDOQI era.

Biuckians A, Scott EC, Meier GH, Panneton JM, Glickman MH.

J Vasc Surg. 2008 Feb;47(2):415-21; discussion 420-1. doi: 10.1016/j.jvs.2007.10.041.

38.

Subintimal angioplasty for the treatment of claudication and critical limb ischemia: 3-year results.

Scott EC, Biuckians A, Light RE, Scibelli CD, Milner TP, Meier GH 3rd, Panneton JM.

J Vasc Surg. 2007 Nov;46(5):959-64. Epub 2007 Oct 1.

39.

What should nephrologists know about hand ischemia?

Asif A, Urbanes A, Scott EC, DeMasi RJ, Bourquelot P.

Semin Dial. 2007 Sep-Oct;20(5):465-74. Review. No abstract available.

PMID:
17897256
40.

Conduits for hemodialysis access.

Scott EC, Glickman MH.

Semin Vasc Surg. 2007 Sep;20(3):158-63. Review.

PMID:
17884616
41.

Educators have hard choices; nationally, not just in kansas.

White A, Meier W, Lovell F, McCoy W, Robinove CJ, Creelan TF, Brun R, Gordon I, West RM, Collier IE, Gish DT, Hartmann WK, Behe MJ, Scott EC.

Science. 2000 Aug 11;289(5481):869d-71d. No abstract available.

PMID:
17839152
42.

Biological design in science classrooms.

Scott EC, Matzke NJ.

Proc Natl Acad Sci U S A. 2007 May 15;104 Suppl 1:8669-76. Epub 2007 May 9.

43.

Complete androgen insensitivity syndrome in a black South African family: a clinical and molecular investigation.

Scott EC, Greenberg TS, Arndt S, Ramsay M, Shires R.

Endocr Pract. 2006 Nov-Dec;12(6):664-9.

PMID:
17229664
44.

Science communication. Public acceptance of evolution.

Miller JD, Scott EC, Okamoto S.

Science. 2006 Aug 11;313(5788):765-6. No abstract available. Erratum in: Science. 2006 Sep 22;313(5794):1739.

PMID:
16902112
45.

Creationism and evolution: it's the American way.

Scott EC.

Cell. 2006 Feb 10;124(3):449-51.

46.

Contact palm burns in toddlers from glass enclosed fireplaces.

Dunst CM, Scott EC, Kraatz JJ, Anderson PM, Twomey JA, Peltier GL.

J Burn Care Rehabil. 2004 Jan-Feb;25(1):67-70.

PMID:
14726741
47.

Behavior favoring transmission in the viviparous monogenean Gyrodactylus turnbulli.

Cable J, Scott EC, Tinsley RC, Harris PD.

J Parasitol. 2002 Feb;88(1):183-4.

PMID:
12053961
48.

The National Childhood Vaccine Injury Act turns fifteen.

Scott EC.

Food Drug Law J. 2001;56(3):351-65. No abstract available.

PMID:
11944644
49.

Essays on science and society. Not (just) in Kansas anymore.

Scott EC.

Science. 2000 May 5;288(5467):813-5. No abstract available.

50.

Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured hepatocytes and microsomes.

Placidi L, Scott EC, Eckoff D, Bynon S, Sommadossi JP.

Drug Metab Dispos. 1999 May;27(5):623-6.

PMID:
10220492

Supplemental Content

Loading ...
Support Center